Intensity TherapeuticsINTS
Recorded

Intensity Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration40 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and welcome to the Intensity Therapeutics Third Quarter 2026 Financial Results Conference Call. Joining the call today is Lewis H. Bender, Intensity's President and CEO, and Joseph Talamo, Intensity's Chief Financial Officer. Shortly before this call, Intensity issued a press release announcing its third quarter 2026 financial results, which is available under the News and Events section of the company website. Shortly after this webcast, a replay of this call will also be posted. Before we begin, the company reminds you that comments made by management during this conference call contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Intensity Therapeutics. These statements include, but are not limited to, statements relating to the company's expected future plans, cash runway, development activities, projected milestones, business activities, or results.

Operator

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties is included in the company's earnings release issued today. For a more complete list and description of risk factors, we encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its Forms 10-K, 10-Q, and eight-Ks. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 5th, 2026. Except as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements. I'll now turn the call over to Mr. Bender, Intensity's President and CEO.

Lewis BenderPresident and CEO

Thank you, Wyatt, and thank you, everyone, for joining us this morning. It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studies, our publications and presentation strategy, our business development activities, and our plans for the rest of 2026 into 2027. First, I will turn the call over to Joe Talamo, our CFO, to discuss our third quarter financial results.

Joseph TalamoCFO

Joe? Thanks, Lou, and good morning.

Joseph TalamoCFO

I'm pleased to join you today and to present a summary of our third quarter 2026 financial results. Our research and development expenses were $2.4 million for the third quarter of 2026, compared with $1.6 million for the same prior year period, reflecting an increase of $876,000, or 56%. Clinical trial expenses for our phase III INVINCIBLE-3 study were $1.5 million during the third quarter of 2026, compared with $1 million for the same prior year period. In the current year quarter, we resumed new patient enrollment activities in the INVINCIBLE-3 study in a limited number of U.S. sites after pausing new site activations and patient enrollment in March 2025 due to funding constraints. During this pause, we continued to treat and monitor patients previously enrolled in the study in cooperation with our CROs.

Joseph TalamoCFO

We have prioritized commencing full patient enrollment and site activations once sufficient incremental funding is obtained. Our clinical trial expenses also included $104,000 for our phase II INVINCIBLE-4 study, which also resumed patient enrollment and treatment in the third quarter of 2026. We expect the INVINCIBLE-4 study costs to increase in the coming quarters as we target completing enrollment in this study by the end of 2027. Lou will provide an operational update on both studies shortly. During the third quarter of 2026, we also initiated a new manufacturing batch of INT230-6, incurring $162,000 in higher manufacturing costs. We expect this batch will be completed in the first quarter of 2027 and will likely be sufficient to fully supply both ongoing clinical studies.

Joseph TalamoCFO

Lastly, research and development employee compensation-related expenses were $184,000 higher during the current quarter due to an estimated bonus accrual in the current year period, compared to no bonus accrual in the prior year period. Turning now to G&A. General and administrative expenses were $1.3 million for the third quarter of 2026 and were unchanged compared with the same prior year period. Within G&A, minor increases in employee compensation-related expenses and consulting expenses were offset by minor decreases in insurance costs during the third quarter of 2026 compared to the same prior year period. Overall, net loss was $3.5 million for the third quarter of 2026, compared with a $2.7 million loss for the third quarter of 2025, representing an increase in net loss of $873,000, or 33%.

Joseph TalamoCFO

Our cash burn from operating activities for the nine months ended September 30, 2026, was $6.7 million, reflecting an average monthly operating activities cash burn of $741,000 over the first nine months of 2026. We estimate that our operating cash burn will average approximately $1 million per month in the final quarter of 2026 as we continue to advance our clinical studies and manufacture the new INT230-6 batch. Turning now to our balance sheet. As of September 30, 2026, we had cash and cash equivalents of $8.5 million. During the third quarter of 2026, we raised $1.5 million in net proceeds from the issuance of common stock under our at-the-market facility. For the nine months ended September 30, 2026, we raised $3.2 million in net proceeds under the at-the-market facility.

Joseph TalamoCFO

We expect to continue to use this facility opportunistically to raise capital, and we will continue to explore other sources of dilutive and non-dilutive capital as we seek to scale up our clinical activities moving forward. With that, I will now turn the call back to Lou for a discussion on our clinical programs and business development activities.

Lewis BenderPresident and CEO

Lou? Thank you, Joe. Well, we are pleased to hold today's earnings call following the positive feedback we received from our stockholders and stakeholders after last quarter's call.

Lewis BenderPresident and CEO

Today, as I said, I will discuss the continued progress that the company has made this quarter in more detail and provide an update on ongoing activities. As you just heard from Joe, we ended the third quarter with about $8.5 million. In the fourth quarter, we continue to evaluate the opportunities to raise capital via the ATM and other types of offerings or financings as opportunities present themselves to us.

Lewis BenderPresident and CEO

Well, now I'm going to update on the phase III INVINCIBLE trial, which is our open-label, randomized controlled clinical study that is testing our drug INT230-6 as monotherapy, meaning just our drug alone, compared to the best standard of care drugs in second and third line treatment for three types of soft tissue sarcomas. On last quarter's call, we reported that we had initiated new patient enrollment in terms of starting the process for that in the INVINCIBLE-3 study in a limited number of U.S. sites. To make this restart happen, this quarter, we added new CROs to help manage this clinical study, including vendors for statistical analysis and a large organization that specializes in receiving computed tomography, known as CT, images from sites around the world electronically during clinical trials.

Lewis BenderPresident and CEO

The purpose of this change is to establish consistency of the reads by radiologists across all sites, whether a patient's cancer is progressing or not, or regressing, compared to a patient's prior scan. Our key sarcoma thought leaders made a few important observations and recommendations. One was a central read, and the other was a recommendation to use a different set of criteria to determine whether a patient's disease was progressing. In the prior version of the amended protocol, we based disease progression on tumor size, which is standard practice for systemic treatments. However, we have learned for our drug, the tumor becomes larger from the injection, from immune cell infiltration, and from the buildup of fluid as the cancer cells die.

Lewis BenderPresident and CEO

While changes in tumor size using criteria such as RECIST or WHO may be standard practice for determining progression for systemic treatments because it's based on the size of the tumor, we believe those criteria are unsuitable for our unique intratumoral drug. Working with the expert radiology group, we finalized a set of criteria to assess whether a patient's cancer is progressing by measuring the tumor's density compared to its baseline. These criteria are referred to as Choi, and they are often used for certain types of sarcoma. While size goes up, density declines using our drug, and using Choi, we think we will have a better assessment of progressive disease. The endpoint remains overall survival. Sites will send their scans for assessment to the central review group, who will return a report on the Choi scores and provide detailed information on density changes for treated and untreated tumors.

Lewis BenderPresident and CEO

Recruitment began in the U.S. in Q3 enrollment, and several sites are activated and seeking patients. We've also filed the needed documentation to restart the phase III in Europe and Canada in Q3. We expect to have approval to begin under the amended protocol in Europe in Q1. As we've mentioned, as incremental capital is raised, we will assess the timing of when additional sites can be activated in the U.S., the E.U., and Canada. Moving to ESMO now. Last month, Kim Guedes, our Vice President of Clinical Operations, and I traveled to Madrid to attend the Annual European Society for Medical Oncology Conference, known as ESMO. We met with several of the INVINCIBLE-3 investigators who remain excited to resume their participation in the study. The last drug approved for second or third line soft tissue sarcoma of the types in our study was in 2016.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day